Urological malignance include a group of
cancers of urinary system, the incidence of
urological cancer shows increasing trend, while the increasing progress in both surgical and non-surgical treatments leads to better
therapeutic effects to the patients of urological oncology. For example, more and more
prostatic cancers are promptly diagnosed in the stage of organ-confined disease which is suitable for curable
therapies, and the surgical technique of radical
prostatectomy is well established and being optimized to guarantee the outcome of
prostate cancer with the decrease of surgical complication. The improvements of
radical cystectomy, along with the optimization of peri-operative intervention, are providing more curable opportunity to elderly and high operative risk patients of
bladder cancer. The breakthrough of basic research on molecular pathogenesis of
renal cell carcinoma, leads to the innovative clinical translation of
molecular targeted therapy in the treatment of metastatic
renal cancer. The great success of research and development on targeted
therapy now are attracting more and more clinical and basic researches which possibly lead to promising novel treatments to urological malignance in the coming future. For the best clinical practice in urological oncology, it is necessary to pay tremendous attention on the advance of both clinical study and laboratory research, which would be the better way to more effectively improve the survival and prognosis of the patients of urological malignance with comprehensive treatments.